Trial Profile
An Early Access Program for Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Expanded access; Therapeutic Use
- Sponsors Janssen Research & Development
- 12 Nov 2020 Status changed from recruiting to completed.
- 08 Dec 2017 New trial record